promoted

Ottawa’s Tetra Bio-Pharma closes $9.2M public offering

Funds will be used to advance the company’s work on QIXLEEF, a therapy to treat uncontrolled pain in advanced cancer patients that’s in the late-phase drug development stage.

Five Canadian business stories to watch this week

Canopy Growth's fourth-quarter results, bank earnings and new GDP figures are among the stories expected to make headlines in the days ahead.

‘Office exodus’ unlikely despite Shopify’s shift to remote-first working, observers say

Commercial real estate executives say many employees’ enthusiasm for remote work is wearing thin and that most companies feel the advantages of face-to-face interaction far outweigh the risks of returning to the office. 

Coping with COVID-19: Behind the Headlines

Michael Curran speaks with OBJ editors David Sali and Peter Kovessy about some of the week’s biggest stories and how Ottawa’s business community is adapting to the ongoing economic challenges.

Ottawa’s Intouch Insight looks to ‘rebuild rapidly’ amid COVID-19 challenges

Tech firm develops software to help brands solicit feedback from and better engage with their customers.

Teen entrepreneur launches app aimed at helping stem spread of COVID-19

Like many teenagers, Ryan Rodrigs has been glued to his smartphone during the COVID-19 lockdown. But in the...

LRT ‘totally changing’ Ottawa’s east-end office landscape, broker says

The Canadian branch of a global real estate investment company has purchased a government-occupied office tower at...

VIA restores some Ottawa-Toronto train trips

Service between Ottawa and Montreal will remain limited to one round-trip daily.

Ottawa office furniture dealers retool for post-COVID workspaces

As the president of the city’s largest office equipment supplier, Bill Toutant didn’t need a reporter to...

Coping With COVID-19: Homebuilders see continued demand in pandemic economy

OBJ publisher Michael Curran speaks with leaders from Ottawa's homebuilding industry about how they are adapting during COVID-19.